Today: 20 May 2026
SK hynix stock breaks 900,000 won — what traders watch next week after the sprint
31 January 2026
2 mins read

SK hynix stock breaks 900,000 won — what traders watch next week after the sprint

Seoul, Feb 1, 2026, 00:38 KST — Market closed

  • SK hynix last closed at 909,000 won, up 5.57%, after briefly trading above 930,000 won.
  • Korea Ratings lifted its unsecured bond rating on the chipmaker to AA+ (stable).
  • A regulatory filing said the company plans to cancel 15.3 million treasury shares on Feb. 9.

SK hynix shares ended the last session at 909,000 won, up 5.57%, for their first close above the 900,000-won mark, after hitting an intraday high of 931,000 won. Seoul Economic Daily said the move was drawing fresh overseas retail attention, with investors swapping tips online on how to access the Korea-listed stock.

That sprint lands as price gauges for memory chips — the products that drive most of the company’s earnings — jump again. DRAMeXchange put the January fixed price for a mainstream 128-gigabit MLC NAND flash product at $9.46, up 64.83% from the prior month, while average prices for some DDR5 modules surged close to 90%.

Broker notes have followed quickly. Korea Investment & Securities raised its target price to 1.3 million won, and analyst Chae Min-sook said higher average selling prices — the average price customers pay — for DRAM and NAND “due to supply shortages will continue for a considerable period.” The stock moved in tandem with a broader chip-led push that sent the benchmark index to another intraday record, with individuals buying while foreigners sold, exchange data showed. Seoul Economic Daily

Credit metrics also turned into a talking point late in the week. Korea Ratings said it upgraded the company’s unsecured bond rating to AA+ (stable) from AA (positive), its first lift in eight years, and argued the business has built a steadier profit base than the old boom-and-bust memory cycle implied. “The company will utilize a significant portion of generated cash flow to build financial buffers,” the agency said. Seoul Economic Daily

The company’s own numbers gave the rally its base. In a Jan. 28 statement, it reported record 2025 results and said it would pay an additional 1 trillion won dividend, equivalent to 1,500 won per share, alongside a plan to cancel 15.3 million treasury shares. Song Hyun Jong said the company would “strengthen our role as a core infrastructure partner in the AI era.” SK hynix Newsroom –

Next up is the mechanics. A disclosure report said the treasury-share cancellation is scheduled for Feb. 9; those shares are stock the company holds in its own name, and cancelling them reduces the share count, lifting per-share metrics if profits hold.

Demand expectations are doing the heavier lifting. High-bandwidth memory (HBM) — a premium form of DRAM used alongside AI accelerators — has been a key driver, and the company has flagged tight supply and strong AI-linked orders even as rivals press harder. Nvidia counts among the major customers in the AI supply chain, and Samsung Electronics is working to close the gap in next-generation HBM, analysts have said.

With the market shut for the weekend, traders will look first for follow-through when Seoul trading resumes on Monday, Feb. 2. Another round of target changes, and any fresh read-through on memory pricing, could decide whether the stock consolidates or keeps running.

But the risk is plain: memory remains cyclical, and a fast move leaves little room for disappointment. A stumble in chip prices, slower AI data-center spending, or quicker progress by competitors would test the profit assumptions built into the latest targets.

For now, the next clear marker is Feb. 9’s planned share cancellation — and whether buyers still show up for the next session after a 900,000-won close.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut
Previous Story

First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut

Alibaba stock price: What to watch after BABA slips 2.7% as AI-chip questions hang over China tech
Next Story

Alibaba stock price: What to watch after BABA slips 2.7% as AI-chip questions hang over China tech

Go toTop